Hassanipour Soheil, Mohammadzadeh Majid, Mansour-Ghanaei Fariborz, Fathalipour Mohammad, Joukar Farahnaz, Salehiniya Hamid, Abdzadeh Elham, Samadani Ali Akbar, Nikbakht Hossein-Ali, Arab-Zozani Morteza
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
J Gastrointest Cancer. 2019 Jun;50(2):193-200. doi: 10.1007/s12029-019-00207-y.
Hepatocellular carcinoma or liver cancer (LC) is one of most important cancer around the world. There are several reports about LC incidence from various Iranian locations with conflicting results. The present study aimed to accomplish a systematic review to estimate the accurate incidence rate of LC among Iranian people.
This systematic review was performed based on the preferred reporting items for systematic reviews and meta-analyses (PRISMA) checklist in 2018. A literature search was conducted using international databases (Medline/PubMed, Scopus, ScienceDirect, and Google Scholar) for English papers and national databases (Scientific Information Database, MagIran, IranMedex, and IranDoc) for Persian papers which estimated incidence rate of LC in any geographical area of Iran. The incidence rate of LC was calculated using random effect model.
Of 171 papers in the primary searches, 15 studies were included by advanced screening and refinement. The age-standardized rate (ASR) of LC was 1.66 (95% CI 1.49-1.83) for males and 1.25 (95% CI 1.12-1.38) for females.
The incidence rate of LC in Iran was lower in comparison to other countries. Afterwards, more studies are necessary to outline the accurate incidence rate and the trend of LC among Iranian population.
肝细胞癌或肝癌（LC）是全球最重要的癌症之一。关于伊朗不同地区肝癌发病率的报道有很多，但结果相互矛盾。本研究旨在进行系统综述，以估计伊朗人群中肝癌的准确发病率。
该系统综述于2018年根据系统综述和Meta分析的首选报告项目（PRISMA）清单进行。使用国际数据库（Medline/PubMed、Scopus、ScienceDirect和谷歌学术）检索英文论文，使用国家数据库（科学信息数据库、MagIran、IranMedex和IranDoc）检索波斯文论文，这些论文估计了伊朗任何地理区域的肝癌发病率。采用随机效应模型计算肝癌发病率。
在初步检索的171篇论文中，经过进一步筛选和细化，纳入了15项研究。男性肝癌年龄标准化率（ASR）为1.66（95%CI 1.49-1.83），女性为1.25（95%CI 1.12-1.38）。
与其他国家相比，伊朗的肝癌发病率较低。此后，有必要进行更多研究以明确伊朗人群中肝癌的准确发病率及其趋势。
